Xiaojing Chen

Xiaojing Chen received her M.S. degree in Biochemistry and Molecular Biology from China. During her previous research, she focused on gene therapy for hemophilia, specifically developing and testing engineered AAV constructs and their delivery into animal models. These works aimed to enhance transduction efficiency and address immunogenicity, thereby advancing the potential for clinical applications. In June 2024, she joined Dr. Ritola’s lab to further her research in gene therapy in neuroscience.